{"title":"psma靶向放射性核素治疗转移性去势抵抗性前列腺癌的进展。","authors":"Jie Wang, Hui Yuan, Jianan Xu, Chongyi Yang","doi":"10.2147/CMAR.S538367","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1859-1869"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412599/pdf/","citationCount":"0","resultStr":"{\"title\":\"Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.\",\"authors\":\"Jie Wang, Hui Yuan, Jianan Xu, Chongyi Yang\",\"doi\":\"10.2147/CMAR.S538367\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.</p>\",\"PeriodicalId\":9479,\"journal\":{\"name\":\"Cancer Management and Research\",\"volume\":\"17 \",\"pages\":\"1859-1869\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412599/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Management and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/CMAR.S538367\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S538367","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.
期刊介绍：
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
